A bipartisan bill was introduced in Congress this week in a bid to lower drugs costs for some hospitals, potentially reviving a contentious battle that the pharmaceutical industry appeared to win nearly two years ago.
The legislation would restore a coveted discount for some 1,200 rural hospitals and a handful of cancer-care hospitals when purchasing drugs with so-called orphan designations, which are granted to medicines for treating rare diseases. A court ruling in 2015 had eliminated the price break.
About the Author Reprints
